Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVHIPEC-2
NL-OMON59003Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Netherlands Cancer Institute. Started Jan 2020; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON59003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59003.